351 related articles for article (PubMed ID: 34114983)
1. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
Hirasawa Y; Yoshimura K; Matsui H; Kubota Y; Ishida H; Arai J; Sakaki M; Oguro N; Shida M; Taniguchi M; Hamada K; Ariizumi H; Ishiguro T; Ohkuma R; Sambe T; Horiike A; Imamura CK; Shiozawa E; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Tate G; Kobayashi S; Tsunoda T
Medicine (Baltimore); 2021 Jun; 100(23):e25774. PubMed ID: 34114983
[TBL] [Abstract][Full Text] [Related]
2. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab.
Yoshikawa Y; Imamura M; Yamaoka K; Kosaka Y; Murakami E; Morio K; Fujino H; Nakahara T; Okamoto W; Yamauchi M; Kawaoka T; Tsuge M; Hiramatsu A; Hayes CN; Aikata H; Fujitaka K; Arihiro K; Hattori N; Chayama K
Clin J Gastroenterol; 2021 Feb; 14(1):283-287. PubMed ID: 33200345
[TBL] [Abstract][Full Text] [Related]
3. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.
McClure T; Cui W; Asadi K; John T; Testro A
BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32912846
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.
Nabeshima S; Yamasaki M; Matsumoto N; Takaki S; Nishi Y; Kawamoto K; Taniwaki M; Ohashi N; Hattori N
Cancer Treat Res Commun; 2021; 26():100270. PubMed ID: 33338849
[TBL] [Abstract][Full Text] [Related]
5. Sclerosing cholangitis in a patient treated with nivolumab.
Talbot S; MacLaren V; Lafferty H
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34049893
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
Kocheise L; Piseddu I; Vonderlin J; Tjwa ET; Buescher G; Meunier L; Goeggelmann P; Fianchi F; Dumortier J; Riveiro Barciela M; Gevers TJG; Terziroli Beretta-Piccoli B; Londoño MC; Frankova S; Roesner T; Joerg V; Schmidt C; Glaser F; Sutter JP; Fründt TW; Lohse AW; Huber S; von Felden J; Sebode M; Schulze K
Front Immunol; 2023; 14():1326078. PubMed ID: 38268921
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report.
Kashima J; Okuma Y; Shimizuguchi R; Chiba K
Cancer Immunol Immunother; 2018 Jan; 67(1):61-65. PubMed ID: 28913619
[TBL] [Abstract][Full Text] [Related]
9. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.
Kawakami H; Tanizaki J; Tanaka K; Haratani K; Hayashi H; Takeda M; Kamata K; Takenaka M; Kimura M; Chikugo T; Sato T; Kudo M; Ito A; Nakagawa K
Invest New Drugs; 2017 Aug; 35(4):529-536. PubMed ID: 28317087
[TBL] [Abstract][Full Text] [Related]
10. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
11. Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis.
Yamamoto T; Mizuno K; Ito T; Yokoyama S; Yamamoto K; Imai N; Ishizu Y; Honda T; Ishikawa T; Kanamori A; Yasuda S; Toyoda H; Yokota K; Hase T; Nishio N; Maeda O; Ishii M; Sone M; Ando Y; Akiyama M; Ishigami M; Kawashima H
Invest New Drugs; 2023 Jun; 41(3):512-521. PubMed ID: 37171720
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report.
Sato K; Hayashi M; Abe K; Fujita M; Takahashi A; Ohira H
Clin J Gastroenterol; 2020 Dec; 13(6):1310-1314. PubMed ID: 32643124
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report.
Suzuki Y; Ishiguro S; Shimada H; Ohgami M; Suzuki M
Cancer Chemother Pharmacol; 2024 Jun; 93(6):633-638. PubMed ID: 38148336
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.
Onoyama T; Takeda Y; Yamashita T; Hamamoto W; Sakamoto Y; Koda H; Kawata S; Matsumoto K; Isomoto H
World J Gastroenterol; 2020 Jan; 26(3):353-365. PubMed ID: 31988594
[TBL] [Abstract][Full Text] [Related]
15. Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case.
Kataoka S; Moriguchi M; Okishio S; Takahashi A; Okuda K; Seko Y; Umemura A; Yamaguchi K; Miyagawa-Hayashino A; Itoh Y
Clin J Gastroenterol; 2022 Apr; 15(2):467-474. PubMed ID: 35201598
[TBL] [Abstract][Full Text] [Related]
16. Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report.
Tanaka T; Sakai A; Tsujimae M; Yamada Y; Kobayashi T; Masuda A; Kodama Y
World J Gastroenterol; 2022 Jul; 28(28):3732-3738. PubMed ID: 36161046
[TBL] [Abstract][Full Text] [Related]
17. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
18. Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret.
Zenouzi R; Liwinski T; Yamamura J; Weiler-Normann C; Sebode M; Keller S; Lohse AW; Schramm C;
Aliment Pharmacol Ther; 2018 Jul; 48(2):169-178. PubMed ID: 29741240
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic.
Davies YK; Cox KM; Abdullah BA; Safta A; Terry AB; Cox KL
J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):61-7. PubMed ID: 18607270
[TBL] [Abstract][Full Text] [Related]
20. Small duct autoimmune sclerosing cholangitis and Crohn colitis in a 10-year-old child. A case report and review of the literature.
Larsen EP; Bayat A; Vyberg M
Diagn Pathol; 2012 Aug; 7():100. PubMed ID: 22891962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
